Focused On-demand Library for Elongation factor G, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96RP9

UPID:

EFGM_HUMAN

Alternative names:

Elongation factor G 1, mitochondrial; Elongation factor G1

Alternative UPACC:

Q96RP9; A6NCI9; B2RCB9; B3KRW1; Q6GTN2; Q96T39

Background:

Elongation factor G, mitochondrial, also known as Elongation factor G1, plays a pivotal role in mitochondrial protein biosynthesis. It is a mitochondrial GTPase that facilitates the GTP-dependent ribosomal translocation step during translation elongation, ensuring the proper movement of tRNA molecules, mRNA, and conformational changes in the ribosome.

Therapeutic significance:

The protein is linked to Combined oxidative phosphorylation deficiency 1, a mitochondrial disease characterized by early, rapidly progressive hepatoencephalopathy. Understanding the role of Elongation factor G, mitochondrial could open doors to potential therapeutic strategies for this condition.